3 Biotech IPOs, $703M Raised for Clinical Trials in Cancer, Immunology & Endocrine Disorders

Bicara Therapeutics has raised $315m in IPO funding, which it will use to finance a study into treating head and neck cancers. The company’s offering originally aimed for 11.7 million shares at $16-$18, but was increased to 17.5 million shares at $18 each. The studies will focus on patients for whom existing treatments have been less successful. The lead therapeutic option will be ficerafusp alfa, a drug developed to treat solid tumors by targeting two cancer growth factors. Bicara is owned largely by Biocon, with an 11.28% stake.